Corporate Fact Sheet

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody technologies.

Company Highlights

- Emerging leader in developing immuno-oncology therapeutics
- Differentiated pipeline comprising eight clinical-stage product candidates
- Leading multispecific antibody technology platforms, with five clinical DART molecules
- Fully-integrated mAb-based development capabilities, including GMP manufacturing
- Collaborations with Janssen, Takeda, Gilead, Servier, Boehringer Ingelheim and Pfizer
- Experienced management team and highly collaborative corporate culture

Pipeline

<table>
<thead>
<tr>
<th>Program (Target)</th>
<th>Indication</th>
<th>Pre-IND</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ONCOLOGY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Margetuximab (HER2)</td>
<td>Breast (3+) &quot;SOPHIA&quot;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Green Cross (Korea only)</td>
</tr>
<tr>
<td></td>
<td>Breast (1-2+)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gastric (+pembrolizumab)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enoblituzumab (B7-H3)</td>
<td>Solid Tumors (mono.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>Solid Tumors (+ipi.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Solid Tumors (+pembro.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MGD006 (CD123 x CD3)</td>
<td>AML/MDS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Servier (EU, Other)</td>
</tr>
<tr>
<td>MGD007 (gpA33 x CD3)</td>
<td>Colorectal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MGD011 (CD19 x CD3)</td>
<td>B-cell Malignancies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Janssen (WW)*</td>
</tr>
<tr>
<td>MGD009 (B7-H3 x CD3)</td>
<td>Solid Tumors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>—</td>
</tr>
<tr>
<td>MGA012 (TBA)</td>
<td>Solid Tumors/Heme</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>—</td>
</tr>
<tr>
<td>MGD013 (PD-1 x LAG-3)</td>
<td>Solid Tumors/Heme</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>—</td>
</tr>
<tr>
<td><strong>AUTOIMMUNE &amp; INFECTIOUS DISEASES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Teplizumab (CD3)</td>
<td>Type 1 Diabetes Prev.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NIDDK/NIH</td>
</tr>
<tr>
<td>MGD010 (CD32B x CD79B)</td>
<td>Autoimmune Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Takeda (WW)*</td>
</tr>
<tr>
<td>MGD014 (HIV x CD3)</td>
<td>HIV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NIAID/NIH</td>
</tr>
</tbody>
</table>

* MacroGenics retains co-promotion rights for MGD011 (in U.S.) and MGD010 (in North America).

MacroGenics’ Antibody Formats

Dual-Affinity Re-Targeting, or DART*, and Trident™ therapeutics enable the targeting of multiple antigens or cells by using a single molecule with an antibody-like structure, for example to recruit a patient’s T cells to destroy targeted cancer cells. In addition to recognizing more than one target, the flexibility of this platform allows for the design of molecules with increased half-life and valency compared to other multi-specific approaches.

Fc-Optimized antibodies mediate the killing of cancer cells through antibody-dependent cellular cytotoxicity, or ADCC, in which antibodies and immune cells cooperate to destroy targets such as tumor cells.

Quick Facts

- **Employees:** 268 (as of 2/5/16)
- **Cash & Investments:** $339M at 12/31/15
- **Shares Outstanding:** 34.3M at 12/31/15
- **Ticker:** MGNX (NASDAQ)
- **Locations:** Rockville, MD, South San Francisco, CA
- **Platforms:**
  - DART® (bispecific)
  - Trident™ (trispecific)
  - Fc Optimization
- **Cancer Stem-like Cells**

Key Collaborations

MacroGenics has developed significant alliances with leading pharmaceutical and biotechnology companies. Ongoing collaboration partners that have provided significant non-dilutive funding include:

- **December 2014**
  - Janssen
- **Sept. & May 2014**
  - Takeda
- **January 2013**
  - Gilead
- **September 2012**
  - Servier
- **October 2010**
  - Boehringer Ingelheim
  - Pfizer
Clinical Product Candidates

**Margetuximab (HER2)**  
*Fc-optimized mAb*  
**Phase 3**

Margetuximab is an Fc-optimized mAb that targets HER2-expressing tumors, including breast, gastroesophageal and other HER2 positive cancers. MacroGenics has engineered the Fc region of margetuximab to enhance its Fc-mediated activities, including improved ADCC. The company is conducting a Phase 3 registration clinical trial (SOPHIA) in metastatic breast cancer patients to demonstrate clinical superiority to trastuzumab. The company is also enrolling a Phase 1b/2 study in combination with pembrolizumab in advanced gastric cancer.

**B7-H3 Programs**

MacroGenics is developing a portfolio of first-in-class therapeutics that target B7-H3, a member of the B7 family of molecules involved in immune regulation and believed to inhibit T-cell activation. The company’s two clinical programs target B7-H3 through complementary mechanisms of action and take advantage of this antigen’s broad expression across solid tumors but limited on normal tissues.

**Enoblituzumab (B7-H3)**  
*Fc-optimized mAb*  
**Phase 1b/2**

Enoblituzumab (MGA271) is an Fc-optimized monoclonal antibody that targets B7-H3. The company is enrolling patients in multiple Phase 1 monotherapy cohorts evaluating seven solid tumors, including prostate, bladder, melanoma and others. The company also continues to enroll patients in two combination studies with either ipilimumab or pembrolizumab.

**MGD009 (B7-H3 x CD3)**  
*Fc-bearing DART*  
**Phase 1**

MGD009 is a DART molecule that recognizes both B7-H3 and CD3. MGD009 is designed to redirect T cells, via their CD3 component, to eliminate cells expressing B7-H3, which is expressed by tumor cells, and on tumor-associated vasculature, stroma and certain tumor-associated leukocytes. MGD009 is being tested in a Phase 1 study in multiple solid tumor types.

Other DART Programs

**MGD006 (CD123 x CD3)**  
*DART*  
**Phase 1**

MGD006 is a humanized DART molecule that recognizes both CD123 and CD3. CD123, the Interleukin-3 receptor alpha chain, is expressed on leukemia and leukemic stem cells, but minimally or not at all on normal hematopoietic stem cells. MacroGenics is enrolling refractory, relapsing AML patients in the dose escalation portion of a Phase 1 clinical trial.

**MGD007 (gpA33 x CD3)**  
*Fc-bearing DART*  
**Phase 1**

MGD007 is a humanized DART molecule that recognizes both gpA33 and CD3. gpA33 is expressed on gastrointestinal tumors, including more than 95% of human colorectal cancers. The company is enrolling patients with metastatic colorectal cancer in a dose escalation portion of a Phase 1 clinical trial.

**MGD011 (CD19 x CD3)**  
*Fc-bearing DART*  
**Phase 1**

MGD011 (also known as JNJ-64052781) is a humanized DART molecule that recognizes both CD19 and CD3 and is being developed for the treatment of B-cell hematological malignancies. MacroGenics licensed worldwide rights to MGD011 to Janssen Biotech, Inc. in early 2015, and retains a U.S. co-promote. Janssen is responsible for clinical development of MGD011.

**MGD010 (CD32B x CD79B)**  
*Fc-bearing DART*  
**Phase 1**

MGD010 is a humanized DART molecule that simultaneously recognizes both CD32B and CD79B, two B-cell surface proteins, for the treatment of autoimmune disorders. MGD010 is designed to inhibit B-cell activation by exploiting the inhibitory function of CD32B, a checkpoint molecule expressed by B cells.